title: Biaryl ether retrohydroxamates as potent, long-lived, orally bioavailable MMP inhibitors.
abstract: A novel series of biaryl ether reverse hydroxamate MMP inhibitors has been developed. These compounds are potent MMP-2 inhibitors with limited activity against MMP-1. Select members of this series exhibit excellent pharmacokinetic properties with long elimination half-lives (7 h) and high oral bioavailability (100%).
authors: Cancer Research Area, Abbott Laboratories, Dept. 47J, Bldg. AP10, 100 Abbott Park Road, Abbott Park, IL 60064, USA. michael.michaelides@abbott.com
authors: M R
authors: MR
authors: Michaelides
authors: J F
authors: JF
authors: Dellaria
authors: J
authors: J
authors: Gong
authors: J H
authors: JH
authors: Holms
authors: J J
authors: JJ
authors: Bouska
authors: J
authors: J
authors: Stacey
authors: C K
authors: CK
authors: Wada
authors: H R
authors: HR
authors: Heyman
authors: M L
authors: ML
authors: Curtin
authors: Y
authors: Y
authors: Guo
authors: C L
authors: CL
authors: Goodfellow
authors: I B
authors: IB
authors: Elmore
authors: D H
authors: DH
authors: Albert
authors: T J
authors: TJ
authors: Magoc
authors: P A
authors: PA
authors: Marcotte
authors: D W
authors: DW
authors: Morgan
authors: S K
authors: SK
authors: Davidsen
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000970:Antineoplastic Agents / Q000097:blood / Q000138:chemical synthesis / Q000493:pharmacokinetics; D001682:Biological Availability; D004791:Enzyme Inhibitors / Q000097:blood / Q000138:chemical synthesis / Q000493:pharmacokinetics; D006207:Half-Life; D006877:Hydroxamic Acids / Q000138:chemical synthesis* / Q000737:chemistry; D020128:Inhibitory Concentration 50; D007275:Injections, Intravenous; D008252:Macaca fascicularis; D061965:Matrix Metalloproteinase Inhibitors
chemical_list: D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D006877:Hydroxamic Acids; D061965:Matrix Metalloproteinase Inhibitors